This interview discusses emerging immunotherapy trends at the 2026 ASCO Annual Meeting, including cancer vaccines, cell-based therapies, ADCs, and AI-driven immune profiling tools poised to reshape oncology care.
Karen Knudsen, PhD, MBA
Advertisement
Articles by Karen Knudsen, PhD, MBA
Pembrolizumab neoadjuvant immunotherapy hits approximately 70% complete responses in desmoplastic melanoma.
Neoadjuvant pembrolizumab reshapes desmoplastic melanoma care, spotlighting sequence integrity, pharmacist-led toxicity readiness, and oncology networks accelerating rare-cancer immunotherapy innovation.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Brain Imaging Study Links Long COVID to Dopamine Neuron Injury, Pointing to Repurposed Treatments
2
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
3
Menopause is Everyone's Business: Final Reflections on VMS Treatment and Pharmacist Empowerment
4
Chronic Low Back Pain Treatments Must Be Weighed Against Risk, Cost, and Limited Benefit
5